Suzhou Basecare Medical (HKSE:02170) ROCE % : -15.52% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Suzhou Basecare Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Suzhou Basecare Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was -15.52%.

Suzhou Basecare Medical ROCE % Historical Data

The historical data trend for Suzhou Basecare Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Basecare Medical ROCE % Chart

Suzhou Basecare Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-543.15

-469.34

-12.36

-7.06

-11.38

Suzhou Basecare Medical Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					-9.95	-3.54	-10.78	-6.66	-15.52

Suzhou Basecare Medical ROCE % Calculation

Suzhou Basecare Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-211.875	/	( ( (1987.594 - 127.922)	+	(2076.087 - 213.577) )	/ 2 )
	=	-211.875	/	( (1859.672	+	1862.51)	/ 2 )
	=	-211.875	/	1861.091
	=	-11.38 %

Suzhou Basecare Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-296.508	/	( ( (2149.248 - 189.9)	+	(2076.087 - 213.577) )	/ 2 )
	=	-296.508	/	( ( 1959.348	+	1862.51 )	/ 2 )
	=	-296.508	/	1910.929
	=	-15.52 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Suzhou Basecare Medical (HKSE:02170) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Suzhou Basecare Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Suzhou Basecare Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Basecare Medical (HKSE:02170) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Suzhou Basecare Medical Corp Ltd (HKSE:02170) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

BioBay, No. 218 Xinghu Street, Unit 101, Building A3, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000

Website

https://www.basecare.cn

Suzhou Basecare Medical Corp Ltd is engaged in providing genetic testing solutions for assisted human reproduction. The company generates revenues from Sales of testing kits, followed by Sales of testing devices and instruments. Basecare focuses on the assisted reproductive sector, such as pre-implantation genetic screening and diagnosis, non-invasive prenatal DNA testing, and chromosome abnormalities testing. It generates revenue from China.

Executives

Orbimed Capital Llc	2102 Investment manager
Lake Bleu Prime Healthcare Master Fund Limited	2201 Interest of corporation controlled by you
Orbimed Partners Master Fund Limited	2101 Beneficial owner
Dawn Capital Fund	2101 Beneficial owner
Dawn Capital Limited	2102 Investment manager
Hh Spr-xiv Cy Holdings Limited	2201 Interest of corporation controlled by you
Hh Spr-xiv Hk Holdings Limited	2101 Beneficial owner
Hh Spr-xiv Holdings L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager

Suzhou Basecare Medical (HKSE:02170) Headlines

No Headlines